BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24397596)

  • 41. Outcome of very late relapse in children with acute lymphoblastic leukemia.
    Rizzari C; Valsecchi MG; Aricò M; Miniero R; Messina C; De Rossi G; Testi AM; Mura R; Galimberti S; Biondi A; Locatelli F; Conter V
    Haematologica; 2004 Apr; 89(4):427-34. PubMed ID: 15075076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transcriptome Analysis Identifies LINC00152 as a Biomarker of Early Relapse and Mortality in Acute Lymphoblastic Leukemia.
    Bárcenas-López DA; Núñez-Enríquez JC; Hidalgo-Miranda A; Beltrán-Anaya FO; May-Hau DI; Jiménez-Hernández E; Bekker-Méndez VC; Flores-Lujano J; Medina-Sansón A; Tamez-Gómez EL; López-García VH; Lara-Ramos JR; Núñez-Villegas NN; Peñaloza-González JG; Flores-Villegas LV; Amador-Sánchez R; Espinosa-Elizondo RM; Martín-Trejo JA; Velázquez-Aviña MM; Merino-Pasaye LE; Pérez-Saldívar ML; Duarte-Rodríguez DA; Torres-Nava JR; Cortés-Herrera B; Solís-Labastida KA; González-Ávila AI; Santillán-Juárez JD; García-Velázquez AJ; Rosas-Vargas H; Mata-Rocha M; Sepúlveda-Robles OA; Mejía-Aranguré JM; Jiménez-Morales S
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Relationship between expression of GYPC and TRIP3 genes and prognosis of acute lymphoblastic leukemia in children].
    Zhang JB; Li XH; Ning F; Guo XS
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):29-32. PubMed ID: 19149918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.
    Hoffmann K; Firth MJ; Beesley AH; Freitas JR; Ford J; Senanayake S; de Klerk NH; Baker DL; Kees UR
    Br J Haematol; 2008 Mar; 140(6):656-64. PubMed ID: 18302714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia.
    Junghanns AS; Wittig S; Woehlecke C; Lehmann T; Arndt C; Gruhn B
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2221-8. PubMed ID: 26224397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor.
    Jaime-Pérez JC; Pinzón-Uresti MA; Jiménez-Castillo RA; Colunga-Pedraza JE; González-Llano Ó; Gómez-Almaguer D
    Hematology; 2018 Jan; 23(1):1-9. PubMed ID: 28580844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
    J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia.
    Choi J; Hwang YK; Sung KW; Kim DH; Yoo KH; Jung HL; Koo HH
    Leuk Res; 2006 Aug; 30(8):1019-25. PubMed ID: 16388850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
    Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
    Franca R; Rebora P; Athanasakis E; Favretto D; Verzegnassi F; Basso G; Tommasini A; Valsecchi MG; Decorti G; Rabusin M
    Pharmacogenomics; 2014 Apr; 15(5):619-27. PubMed ID: 24798719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.
    Oskarsson T; Söderhäll S; Arvidson J; Forestier E; Montgomery S; Bottai M; Lausen B; Carlsen N; Hellebostad M; Lähteenmäki P; Saarinen-Pihkala UM; Jónsson ÓG; Heyman M;
    Haematologica; 2016 Jan; 101(1):68-76. PubMed ID: 26494838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia.
    Jiang N; Koh GS; Lim JY; Kham SK; Ariffin H; Chew FT; Yeoh AE
    Exp Hematol; 2011 Mar; 39(3):321-9, 329.e1-3. PubMed ID: 21130142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.
    Peng HX; Liu XD; Luo ZY; Zhang XH; Luo XQ; Chen X; Jiang H; Xu L
    BMC Cancer; 2017 Jan; 17(1):76. PubMed ID: 28122538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
    Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
    Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
    SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
    Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
    Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.